priors.science/reviews/type-2-diabetes-management

Type 2 Diabetes Management

The current evidence on 50 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

50claims tracked
775primary papers reviewed
1 Jun 2026latest evidence review
Weeklyre-scored against new papers
22 Established · 11 Likely · 17 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableGLP-1 receptor agonist low hypoglycaemia vs sulphonylureasGlp1Established94%20
StableEmpagliflozin cardiovascular mortalityCvroEstablished93%20
StableTirzepatide vs semaglutide HbA1cTirzepatideEstablished93%20
StableLiraglutide major adverse cardiovascular events (LEADER)CvroEstablished92%20
StableSGLT2 inhibitor albuminuria progressionMicrovascularEstablished92%12
StableTirzepatide weight loss vs semaglutideTirzepatideEstablished92%20
StableSemaglutide major adverse cardiovascular events reduction (SUSTAIN-6)CvroEstablished91%20
StableOral semaglutide efficacyGlp1Established91%20
StableBasal analogues vs NPH insulin nocturnal hypoglycaemiaInsulinEstablished91%17
StableTirzepatide vs semaglutide 2.4 mg head-to-headTirzepatideEstablished91%20
StableSemaglutide vs exenatide head-to-headGlp1Established90%18
StableTirzepatide add-on to basal insulinTirzepatideEstablished90%20
StableSemaglutide 2.4 mg vs 1 mg weightGlp1Established89%20
StableGLP-1 receptor agonist weight loss ≥5%Glp1Established88%18
StableFixed-ratio combinations insulin degludec/liraglutide and insulin glargine/lixisenatideInsulinEstablished88%10
StableTirzepatide normoglycaemia ratesTirzepatideEstablished88%20
StableSemaglutide kidney outcomes (FLOW)CvroEstablished87%20
StableRenin-angiotensin-aldosterone system blockade nephropathy protectionMicrovascularEstablished87%15
StableContinuous glucose monitoring reduces hypoglycaemia insulin type 2 diabetesCGMEstablished85%10
StableGLP-1 receptor agonist class cardiovascular benefit generalisationCvroEstablished85%20
StableGLP-1 receptor agonist add-on to basal insulinInsulinEstablished85%9
StableFenofibrate retinopathy independent of lipidsMicrovascularEstablished85%11
StableSemaglutide all-cause mortality (SOUL)CvroLikely83%20
StableWeekly insulin icodec non-inferiorInsulinLikely83%10
StableContinuous glucose monitoring time in range basal insulinCGMLikely81%10
StableIntensive glycaemic control microvascularMicrovascularLikely81%14
StableClosed-loop artificial pancreas system in type 2 diabetesInsulinLikely77%8
StableBasal-plus vs basal-bolus stepwiseInsulinLikely77%10
StableReal-time continuous glucose monitoring HbA1c intensive insulin type 2 diabetesCGMLikely76%12
StableBlood pressure control <130/80 microvascularMicrovascularLikely76%12
StableFlash continuous glucose monitoring HbA1c multiple daily injections type 2 diabetesCGMLikely74%10
StableContinuous glucose monitoring modest benefit non-insulin type 2 diabetesCGMLikely72%14
StableGLP-1 receptor agonist HbA1c reductionGlp1Likely72%20
StableMetformin first-line glycaemic efficacyFirst LineUncertain50%15
StableCardiovascular risk-driven agent selectionFirst LineUncertain50%15
StableChronic kidney disease-driven SGLT2 inhibitor selectionFirst LineUncertain50%15
StableEarly combination vs sequential therapyFirst LineUncertain50%15
StableSulphonylureas higher hypoglycaemia and weight gainFirst LineUncertain50%15
StableIntensive multifactorial risk reductionFirst LineUncertain50%15
StableBariatric surgery type 2 diabetes remission rateRemissionUncertain50%15
StableVery-low-calorie diet remissionRemissionUncertain50%15
StableType 2 diabetes remission durability at 5 yearsRemissionUncertain50%15
StableRemission predictors short durationRemissionUncertain50%15
StableGLP-1 receptor agonist pharmacological remissionRemissionUncertain50%15
StableSGLT2 inhibitor chronic kidney disease progression reductionSglt2Uncertain50%15
StableCanagliflozin renal outcomes (CREDENCE)Sglt2Uncertain50%15
StableDapagliflozin chronic kidney disease outcomes (DAPA-CKD)Sglt2Uncertain50%15
StableSGLT2 inhibitor heart failure hospitalisationSglt2Uncertain50%15
StableSGLT2 inhibitor glycaemic efficacySglt2Uncertain50%15
StableSGLT2 inhibitor diabetic ketoacidosis and genital infection riskSglt2Uncertain50%15
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic